PAR 1.72% 29.5¢ paradigm biopharmaceuticals limited..

Ann: Primary Endpoint Achieved in Phase 2 MPS VI Trial, page-44

  1. 1,216 Posts.
    lightbulb Created with Sketch. 1375
    While this announcement is good in that it allows one of PAR's ardent supporters to try to strike a partnership deal, it also indicates that PAR currently are not close whatsoever to striking a deal.

    While it could have positive outcomes, it also gives Scott access to information that will allow him to identify whether or not PAR will be a viable business going forward and the value of PAR's data package and IP.

    There's no value in critizising his appointment. The only value is in supporting his appointment and trying to find avenues that Scott canuse to strike a deal. I would also support it if Scott were to explore possibly selling PAR's entire data package and IP, but the question is what is it worth?
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
29.5¢
Change
0.005(1.72%)
Mkt cap ! $99.69M
Open High Low Value Volume
28.5¢ 29.5¢ 28.5¢ $64.01K 220.6K

Buyers (Bids)

No. Vol. Price($)
4 125643 28.5¢
 

Sellers (Offers)

Price($) Vol. No.
29.5¢ 12131 3
View Market Depth
Last trade - 11.41am 08/07/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.